title: A resectable case of gastrointestinal stromal tumor derived from the rectal wall after oral targeted molecular therapy with imatinib mesylate.
abstract: We performed targeted molecular therapy in a patient with a non-resectable pelvic gastrointestinal stromal tumor (GIST). Imatinib mesylate was administered at 400-600 mg/day for 6 months, and the tumor became resectable. The patient was a 58-year-old female who visited a gynecologic hospital with the chief complaint of a swollen feeling in the lower abdomen. A pelvic tumor was found by imaging, and the patient was referred to our hospital. Laparotomy was performed, but it was found that the tumor arose from the intestinal serous membrane, rather than from the uterus, and complete excision was difficult. A portion of the tumor tissue was excised, and the abdomen was closed. GIST was diagnosed on postoperative pathological examination, and the tissue was positive for c-kit protein on immunostaining. The tumor had markedly shrunk after oral administration of imatinib mesylate for 6 months, and excision by laparotomy became possible.
authors.affiliation: Department of Obstetrics and Gynecology, Tokai University School of Medicine, Isehara, Kanagawa, Japan. mura-to@is.icc.u-tokai.ac.jp
authors.forename: Toshinari
authors.initials: T
authors.lastname: Muramatsu
authors.forename: Tetsuji
authors.initials: T
authors.lastname: Iida
authors.forename: Takeshi
authors.initials: T
authors.lastname: Hirasawa
authors.forename: Kimitaka
authors.initials: K
authors.lastname: Kikuchi
authors.forename: Isao
authors.initials: I
authors.lastname: Yasui
authors.forename: Masaru
authors.initials: M
authors.lastname: Murakami
authors.forename: Eiko
authors.initials: E
authors.lastname: Yamashita
authors.forename: Seiei
authors.initials: S
authors.lastname: Yasuda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kajiwara
authors.forename: Masanori
authors.initials: M
authors.lastname: Yasuda
authors.forename: R Yoshiyuki
authors.initials: RY
authors.lastname: Osamura
authors.forename: Mikio
authors.initials: M
authors.lastname: Mikami
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D005260:Female; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D006801:Humans; D000068877:Imatinib Mesylate; D008875:Middle Aged; D058990:Molecular Targeted Therapy / Q000379:methods*; D010386:Pelvic Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012007:Rectum / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate